Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evaluating Aggressive B Cell Lymphomas

Leuk Lymphoma; ePub 2017 Sep 3; Raess, et al

Conducting complete immunohistochemical (IHC) and FISH analysis is likely the best way to evaluate aggressive B cell lymphomas (ABCLs), concluded researchers after conducting a study involving 187 individuals. Participants had ABCL, which investigators evaluated using complete IHC and FISH analysis. Among the results:

  • Morphologic and IHC analysis could not identify clinically relevant high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
  • ~Three-fourths of these cases showed conventional diffuse large B-cell lymphoma morphologic features.
  • 14% of MYC-rearranged cases were negative by IHC.
  • Conversely, 60% of cases positive for MYC by IHC did not demonstrate a MYC rearrangement.
  • Analysis by FISH without MYC and BCL2 IHC would have missed 41 cases of double expressor lymphoma.

Citation:

Raess P, Moore S, Cascio M, et al. MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. [Published online ahead of print September 3, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1370547.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Aggressive Lymphomas

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Ibrutinib and venetoclax for relapsed CLL, Niemann C et al. European Society of Hematology Annual Congress 2018. Abstract PF346.

Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505

ADC + BR improves response rate in diffuse large B-cell lymphoma, Sehn LH et al. EHA Congress, Abstract S802.